NCT00358982View on ClinicalTrials.gov

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Hodgkin's Lymphoma
Interventions
DRUG

MGCD0103

MGCD0103 administered orally three times per wek

Trial Locations (5)

60612

Rush University Medical Center, Chicago

68198

Nebraska Medical Center, Omaha

77030

MD Anderson Cancer Center, Houston

M5G 2M9

Princess Margaret Hospital, Toronto

H3A 1A1

Royal Victoria Hospital, Montreal

Sponsors
All Listed Sponsors
lead

Mirati Therapeutics Inc.

INDUSTRY

NCT00358982 - Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter